File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models

TitleAnti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models
Authors
Luo, Ke WangKo, Chun HayYue, Grace G.L.Lee, Michelle Y.Y.Siu, Wing SumLee, Julia K.M.Shum, Wai TingFung, Kwok PuiLeung, Ping ChungLi, GangEvdokiou, AndreasLau, Clara B.S.
KeywordsAnti-osteolysis
Conventional
Metastasis
Metronomic
Zoledronic acid
Issue Date2013
Citation
Cancer Letters, 2013, v. 339, n. 1, p. 42-48 How to Cite?
DOI: http://dx.doi.org/10.1016/j.canlet.2013.07.024
AbstractThis study aims to determine the effect of metronomic (0.0125. mg/kg twice a week for 4. weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1. mg/kg once in 4. weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer. © 2013 Elsevier Ireland Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/343131
ISSN
0304-3835
2023 Impact Factor: 9.1
2023 SCImago Journal Rankings: 2.595

 

DC FieldValueLanguage
dc.contributor.authorLuo, Ke Wang-
dc.contributor.authorKo, Chun Hay-
dc.contributor.authorYue, Grace G.L.-
dc.contributor.authorLee, Michelle Y.Y.-
dc.contributor.authorSiu, Wing Sum-
dc.contributor.authorLee, Julia K.M.-
dc.contributor.authorShum, Wai Ting-
dc.contributor.authorFung, Kwok Pui-
dc.contributor.authorLeung, Ping Chung-
dc.contributor.authorLi, Gang-
dc.contributor.authorEvdokiou, Andreas-
dc.contributor.authorLau, Clara B.S.-
dc.date.accessioned2024-05-10T09:05:42Z-
dc.date.available2024-05-10T09:05:42Z-
dc.date.issued2013-
dc.identifier.citationCancer Letters, 2013, v. 339, n. 1, p. 42-48-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10722/343131-
dc.description.abstractThis study aims to determine the effect of metronomic (0.0125. mg/kg twice a week for 4. weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1. mg/kg once in 4. weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer. © 2013 Elsevier Ireland Ltd.-
dc.languageeng-
dc.relation.ispartofCancer Letters-
dc.subjectAnti-osteolysis-
dc.subjectConventional-
dc.subjectMetastasis-
dc.subjectMetronomic-
dc.subjectZoledronic acid-
dc.titleAnti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2013.07.024-
dc.identifier.pmid23896464-
dc.identifier.scopuseid_2-s2.0-84883461153-
dc.identifier.volume339-
dc.identifier.issue1-
dc.identifier.spage42-
dc.identifier.epage48-
dc.identifier.eissn1872-7980-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats